Business
KRTL Holding Group, Inc. and Aura Nootropics Advance Thailand-Focused Methylene Blue Initiative
KRTL Holding Group, Inc. and Aura Nootropics Advance Thailand-Focused Methylene Blue Initiative.
About this update from Krtl Holding Group, Inc
[{"type":"text","content":"KRTL Holding Group, Inc. (“KRTL\r\nHolding” or the “Company”) announced today that its subsidiary, KRTL Biotech\r\nInc. (“KRTL Biotech”), and Aura Nootropics, Inc. (“AURA”) are continuing to\r\nadvance their previously announced strategic collaboration relating to\r\nmethylene blue-based consumer product opportunities beginning in Thailand.\r\nFollowing the Parties’ recently\r\nannounced partnership framework, KRTL Biotech and AURA are now coordinating\r\noperational, regulatory, and commercial evaluation efforts relating to\r\npotential methylene blue (“MB”) product applications in international consumer\r\nmarkets.\r\nThe Parties are currently evaluating\r\npotential pathways for the lawful importation, formulation integration, and\r\ncommercialization of methylene blue-based products, subject to applicable\r\nregulatory requirements, product classification review, manufacturing\r\nstandards, labeling requirements, and any additional agreements that may be\r\nrequired.\r\nAs part of these efforts, KRTL\r\nBiotech and AURA are also assessing regional manufacturing, supply-chain, and\r\nproduction opportunities within Thailand to support scalability, operational\r\nefficiency, and long-term commercial viability as the initiative develops.\r\nThe collaboration continues to\r\ncombine KRTL Biotech’s access to a proprietary methylene blue formulation and\r\nregulatory positioning with AURA’s established network in Thailand and\r\nexperience in product development, branding, distribution strategy, and market\r\naccess.\r\nThe Company indicated that Thailand\r\nis expected to serve as an initial strategic market for evaluating product\r\ndevelopment and commercialization opportunities, with broader regional\r\nexpansion opportunities to be considered as the collaboration progresses.\r\nLeadership of KRTL Biotech Inc.\r\nstated, “Following the establishment of our strategic relationship with AURA,\r\nour focus is now centered on evaluating the operational and regulatory\r\nframework necessary to support future commercialization opportunities. AURA’s\r\nmarket knowledge, product-development capabilities, and relationships in\r\nThailand provide an important foundation as we work to assess appropriate\r\npathways for product integration, importation, manufacturing, and long-term\r\nmarket development.”\r\nKRTL Holding stated that the\r\...